These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

445 related items for PubMed ID: 18397717

  • 1. Switch of ESA therapy from darbepoetin-alpha to epoetin-beta in hemodialysis patients: a single-center experience.
    Biggar P, Ketteler M, Hennemann H, Dömling R.
    Clin Nephrol; 2008 Mar; 69(3):185-92. PubMed ID: 18397717
    [Abstract] [Full Text] [Related]

  • 2. Dose conversion ratio one year after switching from epoetin alpha to darbepoetin alpha in Japanese hemodialysis patients.
    Hirai T, Nakashima A, Shiraki N, Takasugi N, Yorioka N.
    Int J Artif Organs; 2010 May; 33(5):283-9. PubMed ID: 20593349
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
    Fischbach M, Wühl E, Reigner SCM, Morgan Z, Schaefer F.
    Clin J Am Soc Nephrol; 2018 Jan 06; 13(1):81-90. PubMed ID: 29097481
    [Abstract] [Full Text] [Related]

  • 4. Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta.
    Bock HA, Hirt-Minkowski P, Brünisholz M, Keusch G, Rey S, von Albertini B, Swiss EFIXNES trial investigators.
    Nephrol Dial Transplant; 2008 Jan 06; 23(1):301-8. PubMed ID: 17890745
    [Abstract] [Full Text] [Related]

  • 5. Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients.
    Fang YW, Chang CH.
    Perit Dial Int; 2009 Jan 06; 29(2):199-203. PubMed ID: 19293358
    [Abstract] [Full Text] [Related]

  • 6. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.
    Horowitz J, Agarwal A, Huang F, Gitlin M, Gandra SR, Cangialose CB.
    J Manag Care Pharm; 2009 Jan 06; 15(9):741-50. PubMed ID: 19954265
    [Abstract] [Full Text] [Related]

  • 7. Dose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM study.
    Choi P, Farouk M, Manamley N, Addison J.
    Adv Ther; 2013 Nov 06; 30(11):1007-17. PubMed ID: 24173670
    [Abstract] [Full Text] [Related]

  • 8. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials.
    Mann J, Kessler M, Villa G, Martinez-Castelao A, Feldt-Rasmussen B, Cruz J, Hörl WH, Mattin C, Praml C, Wilkie M.
    Clin Nephrol; 2007 Mar 06; 67(3):140-8. PubMed ID: 17390738
    [Abstract] [Full Text] [Related]

  • 9. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA, Walker R, Australian Renal Anaemia Group.
    Nephrology (Carlton); 2007 Apr 06; 12(2):126-9. PubMed ID: 17371333
    [Abstract] [Full Text] [Related]

  • 10. Switch From Epoetin Beta to Darbepoetin Alfa Treatment of Anemia in Taiwanese Hemodialysis Patients: Dose Equivalence by Hemoglobin Stratification.
    Liao SC, Hung CC, Lee CT, Lee CH, Lee CC, Lin CL, Sun CY, Cheng BC, Yang CC, Wu CH, Chen JB.
    Ther Apher Dial; 2016 Aug 06; 20(4):400-7. PubMed ID: 27060362
    [Abstract] [Full Text] [Related]

  • 11. Preservation of anemia control and weekly ESA dosage after conversion from PEG-Epoetin beta to darbepoetin alfa in adult hemodialysis patients: the TRANSFORM study.
    Donck J, Gonzalez-Tabares L, Chanliau J, Martin H, Stamatelou K, Manamley N, Farouk M, Addison J.
    Adv Ther; 2014 Nov 06; 31(11):1155-68. PubMed ID: 25367412
    [Abstract] [Full Text] [Related]

  • 12. Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients.
    Kuwahara M, Hasumi S, Mandai S, Tanaka T, Shikuma S, Akita W, Mori Y, Sasaki S.
    Clin Exp Nephrol; 2014 Oct 06; 18(5):755-62. PubMed ID: 24317507
    [Abstract] [Full Text] [Related]

  • 13. [Resistance index to epoetin alpha and to darbepoetin-alpha in chronic hemodialysis patients: a cohort study].
    Pérez-García R, Rodríguez Benítez P, Jofre R, López-Gómez JM, Villaverde MT, Blanco A, Blanco S, Sánchez M.
    Nefrologia; 2007 Oct 06; 27(3):340-9. PubMed ID: 17725454
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S, Boulton H, Gokal R.
    J Nephrol; 2004 Oct 06; 17(5):687-92. PubMed ID: 15593036
    [Abstract] [Full Text] [Related]

  • 18. Long-term maintenance of hemoglobin levels in hemodialysis patients treated with bi-weekly epoetin beta pegol switched from darbepoetin alfa: a single-center, 12-month observational study in Japan.
    Kawai T, Kusano Y, Yamada K, Ueda C, Kawai A, Masaki T.
    J Artif Organs; 2019 Jun 06; 22(2):146-153. PubMed ID: 30426250
    [Abstract] [Full Text] [Related]

  • 19. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
    Chen HH, Tarng DC, Lee KF, Wu CY, Chen YC.
    J Nephrol; 2008 Jun 06; 21(4):543-9. PubMed ID: 18651544
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.